Lilly's Olomorasib Receives US FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed Metastatic KRAS G12C-Mutant Lung Cancers

Lilly's Olomorasib Receives US FDA's Breakthrough Therapy Designation for the Treatment of Certain Newly Diagnosed Metastatic KRAS G12C-Mutant Lung Cancers

Eli Lilly and Company announced that the US FDA has granted Breakthrough Therapy designation to olomorasib, in combination with anti-PD-1 therapy KEYTRUDA for the first-line treatment of patients with unresectable advanced or metastatic NSCLC with a KRAS G12C mutation and PD-L1 expression ≥ 50%. [Eli Lilly and Company] Press Release